Hanmi Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Hanmi Science is a holding company, listed on KOSPI (Korea's main stock exchange), that earns income through dividends from its subsidiaries, patent and trademark royalties, a healthcare business, and a pharmaceutical wholesale operation.
Its healthcare arm develops and distributes medical devices, consumer health products, beauty-care items, and pharmacy-focused IT software. Its wholesale division supplies medicines, health supplements, and pharmacy equipment to pharmacies and hospitals through both a dedicated online platform and a nationwide sales network.
Summary is AI-generated and may contain errors · figures from DART filings
As an operating holding company, it generates its own revenues directly, not solely through dividends, while also coordinating long-term strategy and sharing risk across new-drug development within its group.
Hanmi Science in five facts
What does Hanmi Science do?
Hanmi Science is a holding company, listed on KOSPI (Korea's main stock exchange), that earns income through dividends from its subsidiaries, patent and trademark royalties, a healthcare business, and a pharmaceutical wholesale operation.
Where is Hanmi Science listed and in which sector?
Hanmi Science (Korean name: 한미사이언스) trades under KRX code 008930 on KOSPI, the main board of the Korea Exchange. It is classified in the Financials sector, Diversified Financials.
How large is Hanmi Science?
Its market capitalisation was US$2.3B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Hanmi Science's latest annual revenue and operating profit?
For fiscal year 2025, Hanmi Science reported revenue of US$1B, operating profit of US$104.7M and net income of US$88.8M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 5.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meeting (notice)Oct 16
- Earnings release schedule notice (notice)Oct 16
- Report on large shareholdings (5% rule) (standard)Oct 16
- Change in shares held by the largest shareholderOct 15
- DisclosureOct 7
- Report on large shareholdings (5% rule) (standard)Oct 7
- Executives/major shareholders' securities trading planOct 7
- Investor relations (IR) meeting (notice)Oct 2
- DisclosureSep 30
- Material management matter relevant to investment decisions (subsidiary)Sep 29
- Report on large shareholdings (5% rule) (standard)Sep 29
- Report on large shareholdings (5% rule) (standard)Sep 23
- Executives/major shareholders' securities trading planSep 23
- Report on securities held by executives/major shareholdersSep 11
- Change in shares held by the largest shareholderSep 1
- Report on securities held by executives/major shareholdersSep 1
- Report on large shareholdings (5% rule) (standard)Sep 1
- Treasury share disposal: results report
Hanmi Science Co., Ltd. completed disposal of 35,501 treasury common shares to officers and employees between August 4-5, 2026 for a combined US$918K, following its July 28, 2026 material event report; the actual number disposed differed from the planned 40,844 shares due to share price and performance-evaluation changes.
Treasury Shares · Aug 7 - Material event report (treasury share disposal) (subsidiary)
Hanmi Pharm's board decided on July 28, 2026 to dispose of 10,402 treasury common shares (valued at US$268.72 each, totaling US$2.8M) between July 29 and August 28, 2026, granting them to 644 employees as productivity incentive (RSA) shares (7,562 shares) and to 18 employees as major-performance incentive (RSU) shares (2,840 shares), via Shinhan Investment Corp.
Treasury Shares · Jul 28 - Operating results (consolidated) (preliminary) (fair disclosure)
Hanmi Science filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$253M (+8.7% year on year), operating profit of US$40.7M (+70.9% year on year) and net income of US$30M (+54.2% year on year).
Earnings · Jul 28 - Material event report (treasury share disposal)
Hanmi Science disclosed a plan to sell treasury shares worth US$998K, about 0.0% of its market value.
Treasury Shares · Jul 28 - Material event report (treasury share disposal) (subsidiary)
Hanmi Science's subsidiary JVM Co., Ltd. decided to dispose of 16,746 common treasury shares (US$14.95 per share; total US$250K) between July 21 and August 21, 2026, to pay employee productivity incentives (PI), transferring the shares directly to employees' brokerage accounts via NH Investment & Securities.
Treasury Shares · Jul 20 - Supply contract signed (subsidiary)
Hanmi Science disclosed a subsidiary's supply contract with Organon International GmbH, worth US$35.1M, about 3.4% of the subsidiary's recent annual revenue, running through May 2036.
Supply contract · May 21 - Operating results (consolidated) (preliminary) (fair disclosure)
Hanmi Science filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$240M (+6.5% year on year), operating profit of US$22.8M (+24% year on year) and net income of US$28.7M (+73% year on year).
Earnings · Apr 30 - Cash/in-kind dividend decision (subsidiary)Dividend · Mar 13
- Cash/in-kind dividend decision (subsidiary)Dividend · Mar 12
- Cash/in-kind dividend decision
Hanmi Science declared a cash dividend of US$0.20 per share, equal to about 0.79% of the recent share price.
Dividend · Mar 12 - Treasury share disposal: results reportTreasury Shares · Feb 13
- Change of 30% or more in revenue or profit/loss structure (15% for large companies) (subsidiary)
Hanmi Science reported a subsidiary's consolidated results for FY2025: revenue of US$1.06B (+3.48% year on year), operating profit of US$177M (+19.25% year on year) and net income of US$129M (+33.92% year on year).
Earnings · Feb 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Hanmi Science reported consolidated results for FY2025: revenue of US$929M (+5.7% year on year), operating profit of US$94.9M (+40.2% year on year) and net income of US$79.3M (+104.2% year on year).
Earnings · Feb 5 - Operating results (consolidated) (preliminary) (fair disclosure)
Hanmi Science filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$236M (+3.7% year on year), operating profit of US$25.8M (+197.4% year on year) and net income of US$21.3M (from a loss a year earlier).
Earnings · Feb 5 - Supply contract signed (subsidiary)Supply contract · Jan 28
- Material event report (treasury share disposal) (subsidiary)Treasury Shares · Jan 9
- Material event report (treasury share disposal) (subsidiary)Treasury Shares · Jan 9
- Material event report (treasury share disposal)Treasury Shares · Jan 9